Sproxil partners with Nigeria’s NMEP, PVAC to combat malaria through AI-powered surveillance

Michael Adesina

Sproxil, an African healthtech innovator, has announced a partnership with Nigeria’s National Malaria Elimination Programme (NMEP) and the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) to strengthen the fight against malaria across the country.

The partnership, formalized through a Memorandum of Understanding at the Access to Markets event hosted by Investing in Innovation Africa (i3), aims to improve access to malaria diagnostics and treatments while providing critical real-time surveillance data to health authorities.

Transforming Malaria Response with AI and Real-Time Data
Sproxil’s innovative test, treat, and track model, powered by artificial intelligence, enables unprecedented visibility into malaria distribution and treatment patterns across Nigeria.

The AI system interprets rapid diagnostic tests taken by healthcare workers, pharmacies, and patent medicine vendors, determining whether results are positive, negative, or invalid. This generates Nigeria’s first real-time Test Positivity Rate map, giving NMEP actionable insights to track disease patterns, monitor medication distribution, and ensure accountability throughout the healthcare supply chain.

The initiative supports Nigeria’s Affordable Diagnostics and Medicine for Malaria Funding Model (ADMFm), a co-payment mechanism where government and pharmaceutical manufacturers share costs to reduce the price of ACTs and rapid diagnostic tests. This ensures affordability and widespread availability, particularly in rural areas where the malaria burden is highest.

Sproxil will deploy NAFDAC-mandated traceability and mobile authentication services on ACTs distributed through the programme, protecting patients from counterfeit medicines while generating the surveillance data NMEP needs to meet its targets of reducing malaria prevalence below 10% and cutting deaths to under 50 per 1,000 live births.

“We are honored to partner with NMEP and PVAC in deploying AI-enhanced surveillance infrastructure that transforms every consumer product verification into timely epidemiological intelligence,” said Dr. Ashifi Gogo, CEO and Founder of Sproxil. “This partnership demonstrates that African-led solutions, when properly supported, can drive continental health transformation while ensuring affordable antimalarials reach the children and families who need them most.”

Sproxil is an African healthtech company that leverages AI and mobile technology to improve access to quality healthcare and combat counterfeit medications.

Through innovative product verification and health surveillance solutions, Sproxil empowers consumers, healthcare providers, and governments to make informed health decisions.